ABIVAX SA (2X1.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:2X1 • FR0012333284

101 EUR
+3.4 (+3.48%)
Last: Feb 10, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to 2X1. 2X1 was compared to 81 industry peers in the Biotechnology industry. Both the profitability and financial health of 2X1 have multiple concerns. 2X1 is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • 2X1 had negative earnings in the past year.
  • In the past year 2X1 has reported a negative cash flow from operations.
  • 2X1 had negative earnings in each of the past 5 years.
  • In the past 5 years 2X1 always reported negative operating cash flow.
2X1.DE Yearly Net Income VS EBIT VS OCF VS FCF2X1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of 2X1 (-146.87%) is worse than 81.48% of its industry peers.
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROIC N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
2X1.DE Yearly ROA, ROE, ROIC2X1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

  • 2X1 does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2X1.DE Yearly Profit, Operating, Gross Margins2X1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. Health

2.1 Basic Checks

  • 2X1 has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 2X1 has more shares outstanding
  • Compared to 1 year ago, 2X1 has a worse debt to assets ratio.
2X1.DE Yearly Shares Outstanding2X1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
2X1.DE Yearly Total Debt VS Total Assets2X1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 17.11 indicates that 2X1 is not in any danger for bankruptcy at the moment.
  • 2X1 has a better Altman-Z score (17.11) than 92.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 17.11
ROIC/WACCN/A
WACCN/A
2X1.DE Yearly LT Debt VS Equity VS FCF2X1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

  • A Current Ratio of 0.77 indicates that 2X1 may have some problems paying its short term obligations.
  • 2X1 has a worse Current ratio (0.77) than 75.31% of its industry peers.
  • 2X1 has a Quick Ratio of 0.77. This is a bad value and indicates that 2X1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.77, 2X1 is doing worse than 71.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.77
Quick Ratio 0.77
2X1.DE Yearly Current Assets VS Current Liabilites2X1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 18.52% over the past year.
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • 2X1 is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -0.46% yearly.
  • 2X1 is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 175.58% yearly.
EPS Next Y-20.7%
EPS Next 2Y33.35%
EPS Next 3Y-0.46%
EPS Next 5YN/A
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y175.58%

3.3 Evolution

2X1.DE Yearly Revenue VS Estimates2X1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
2X1.DE Yearly EPS VS Estimates2X1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 2X1. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 2X1. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2X1.DE Price Earnings VS Forward Price Earnings2X1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100 -150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
2X1.DE Per share data2X1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.35%
EPS Next 3Y-0.46%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for 2X1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABIVAX SA

FRA:2X1 (2/10/2026, 7:00:00 PM)

101

+3.4 (+3.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-15
Earnings (Next)03-23
Inst Owners41.18%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap7.92B
Revenue(TTM)N/A
Net Income(TTM)-176.24M
Analysts85.71
Price Target127.99 (26.72%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12.15%
PT rev (3m)23%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-16.68%
EPS NY rev (3m)-26.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.8
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0
BVpS-0.61
TBVpS-0.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -146.87%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.48%
ROA(5y)-60.32%
ROE(3y)-451.51%
ROE(5y)-460.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 44.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.77
Quick Ratio 0.77
Altman-Z 17.11
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.18%
Cap/Depr(5y)310.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.26%
EPS Next Y-20.7%
EPS Next 2Y33.35%
EPS Next 3Y-0.46%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year91.53%
Revenue Next 2Y16.32%
Revenue Next 3Y246.09%
Revenue Next 5Y175.58%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.57%
EBIT Next 3Y14.09%
EBIT Next 5YN/A
FCF growth 1Y-141.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-142.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABIVAX SA / 2X1.DE FAQ

What is the ChartMill fundamental rating of ABIVAX SA (2X1.DE) stock?

ChartMill assigns a fundamental rating of 1 / 10 to 2X1.DE.


What is the valuation status of ABIVAX SA (2X1.DE) stock?

ChartMill assigns a valuation rating of 0 / 10 to ABIVAX SA (2X1.DE). This can be considered as Overvalued.


What is the profitability of 2X1 stock?

ABIVAX SA (2X1.DE) has a profitability rating of 0 / 10.